# US 2012/0258988 A1 · Therapeutic or prophylactic agent for diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0258988 A1
- Document ID: US20120258988A1
- Status: Published application
- Kind: A1
- Application number: 13/509,483
- Filed: 2010-11-12
- Published: 2012-10-11
- Earliest claimed: 2009-11-13
- Assignees: The University of Tokyo; Toray Industries, Inc.
- Inventors: Takehiro Takahashi; Hiroki Kumagai; Takashi Kadowaki; Naoto Kubota; Tetsuya Kubota
- Web page: https://patentgrep.com/patent/US20120258988A1

## CPC

- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 31/10: Antimycotics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A therapeutic or prophylactic agent for diabetes includes a thiazolidine derivative as a PPAR-γ agonist as an effective component which exhibits a reduced side effect of the PPAR-γ agonist. The therapeutic or prophylactic agent for diabetes includes a particular IP agonist such as beraprost sodium (BPS), and a thiazolidine derivative such as pioglitazone or a pharmaceutically acceptable salt thereof. Since the therapeutic or prophylactic agent exhibits a sufficiently effective hypoglycemic action without being accompanied by side effects characteristic to PPAR-γ agonists, the agent is useful as a highly safe and effective therapeutic or prophylactic agent for diabetes.

## Claims

### Claim 1

A therapeutic or prophylactic agent for diabetes, comprising a combination of a prostaglandin I2 derivative represented by Formula (I):
(wherein
R1 represents a pharmaceutically acceptable cation or hydrogen;
R2 represents hydrogen or C2-C10 acyl;
R3 represents hydrogen or C2-C10 acyl;
R4 represents hydrogen, methyl or ethyl;
R5 represents C1-C5 linear alkyl;
A represents
i) —CH2—CH2—; or
ii) trans —CH═CH—; and
X represents trans —CH═CH—)
and a thiazolidine derivative.

### Claim 2 (depends on 1)

The therapeutic or prophylactic agent according to claim 1, wherein, in said Formula (I), both R2 and R3 are hydrogen, both R4 and R5 are methyl, and A is —CH2—CH2—.

### Claim 3 (depends on 2)

The therapeutic or prophylactic agent according to claim 2, wherein said prostaglandin I2 derivative represented by Formula (I) is beraprost sodium.

### Claim 4 (depends on 1)

The therapeutic or prophylactic agent according to claim 1, wherein said thiazolidine derivative is pioglitazone or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 2)

The therapeutic or prophylactic agent according to claim 2, wherein said thiazolidine derivative is pioglitazone or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 3)

The therapeutic or prophylactic agent according to claim 3, wherein said thiazolidine derivative is pioglitazone or a pharmaceutically acceptable salt thereof.

### Claim 7

A method of treating diabetes comprising administering 1) a prostaglandin I2 derivative represented by Formula (I):
and 2) a thiazolidine derivative to a mammal in an amount that is less than therapeutically effective if administered alone such that, in combination, the prostaglandin I2 derivative and the thiazolidine derivative cause therapeutically effective hypoglycemic and glucose tolerance-improving action without causing side effects characteristic of PPAR-γ agonists.

### Claim 8 (depends on 7)

The method according to claim 7, wherein, in said Formula (I), both R2 and R3 are hydrogen, both R4 and R5 are methyl, and A is —CH2—CH2—.

### Claim 9 (depends on 8)

The method according to claim 8, wherein said prostaglandin I2 derivative represented by Formula (I) is beraprost sodium.

### Claim 10 (depends on 7)

The method according to claim 7, wherein said thiazolidine derivative is pioglitazone or a pharmaceutically acceptable salt thereof.
